WO2020005785A1 - Composition de liaison de pyrogène et son utilisation dans le traitement et la prévention du sepsis - Google Patents

Composition de liaison de pyrogène et son utilisation dans le traitement et la prévention du sepsis Download PDF

Info

Publication number
WO2020005785A1
WO2020005785A1 PCT/US2019/038618 US2019038618W WO2020005785A1 WO 2020005785 A1 WO2020005785 A1 WO 2020005785A1 US 2019038618 W US2019038618 W US 2019038618W WO 2020005785 A1 WO2020005785 A1 WO 2020005785A1
Authority
WO
WIPO (PCT)
Prior art keywords
subject
pyrogen
chlorhexidine
site
sepsis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/038618
Other languages
English (en)
Inventor
Carolyn L. Twomey
Samuel ZAIDSPINER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovation Technologies Inc
Original Assignee
Innovation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovation Technologies Inc filed Critical Innovation Technologies Inc
Publication of WO2020005785A1 publication Critical patent/WO2020005785A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the management and treatment of a wound, a surgical site, a surgical incision, or otherwise infection-prone tissues in the body has three primary objectives: (1) prevention of infection, (2) preservation and/or restoration of function, and (3) preservation and/or restoration of cosmetic appearance.
  • the most important of these objectives is the prevention of infection. Success in the prevention of infection directly affects the healing process and the degree to which function and cosmetic appearance can be preserved and/or restored.
  • the number and virulence of bacteria present at a site are critical determinants of whether the site becomes infected.
  • Experimental evidence suggests that a critical level of bacteria is approximately 10 5 organisms per gram of tissue. Below this level, a site or a tissue typically heals; at levels greater than 10 5 bacteria per gram of tissue, infections often develop. Dirty wounds, or wounds that have not been treated within six hours, are likely to be contaminated with bacteria at levels that are higher than the critical level. Reducing the number of bacteria in and around the wound is critical for avoiding infection and expediting wound healing.
  • sepsis a condition known as sepsis, where the body initiates an extreme immune response to the infection that can cause damage to tissues and organs. Sepsis can present in the form of fever, increased heart rate, decreased blood pressure, and confusion, among other serious symptoms.
  • Fever in particular, may develop in critically ill patients as a result of the production of fever-inducing agents, or pyrogens, by the infecting bacteria.
  • pyrogen is an endotoxin compound, a lipopolysaccharide (LPS), which is a potent toxin present in the cell walls of Gram-negative, and some Gram-positive bacteria.
  • LPS lipopolysaccharide
  • a fever is an inflammatory response that affects the entire body, resulting in an increase in body temperature above a subject’s baseline temperature. Pyrogenic fever is a common response to sepsis, and occurs through several mechanisms.
  • Exogenous pyrogens such as, e.g., those produced by microorganisms, and endogenous pyrogens, such as, e.g., the cytokines IL-l, IL-6 and TNF-a, interact with the hypothalamus, the section of the brain that maintains homeostasis in the body.
  • the part of the hypothalamus affected by this interaction lacks a blood- brain barrier, allowing it to be stimulated directly by pyrogenic substances. Stimulation of the hypothalamus leads to increased synthesis of, for example, PGE 2 and ceramide, which act to slow the firing rate of the warm sensitive neurons in the hypothalamus, resulting in an increase in body temperature.
  • a low-level fever can assist the body in immune defense by, for example, stimulating the leukocytes to kill pathogens, as well as by inhibiting the growth of certain pathogens that do not thrive at elevated temperatures; however, when such an immune response becomes too strong, the results can include tissue and organ damage and, in severe cases, death ln extreme cases, for example, if a bacterial infection reaches the bloodstream, endotoxemia can result, where large quantities of endotoxins, or pyrogens, are released into the blood. This can eventually lead to a condition known as septic shock.
  • the strong immune and inflammatory responses that occur with septic shock can cause a severe drop in blood pressure, intravascular blood clotting, development of thrombi and emboli that block blood vessels and lead to tissue death, multiple organ failure, and even death of the patient.
  • Sepsis is a widespread problem that affects hundreds of thousands of people each year. While many cases of sepsis are linked to hospital acquired infections (HAI), doctors’ offices, nursing homes and/or other healthcare facilities, many other cases are acquired outside of these facilities, for example, at home, school, or work. Any infection can lead to sepsis, from, for example, a simple cut, to food poisoning, to a urinary tract infection.
  • HAI hospital acquired infections
  • the subject invention provides materials and methods for preventing and/or treating sepsis by, for example, decreasing the amount of bioavailable pyrogens in a subject’s body.
  • the subject invention provides compositions and methods of their use for reducing the activity of pyrogenic substances, or pyrogens, in a subject diagnosed with an infection and/or with sepsis, or in a subject at risk of developing sepsis.
  • the compositions of the subject invention are capable of binding to pyrogens and rendering them incapable of inducing the immune response that leads to sepsis.
  • the subject invention provides pyrogen-binding compositions comprising chlorhexidine. It has been found that the subject compositions, which, in preferred embodiments, comprise a low concentration chlorhexidine without other excipients, can be administered to a subject according to the procedures of the subject invention without causing hemolysis.
  • the active agent of the subject compositions is a salt of chlorhexidine, such as, for example, chlorhexidine gluconate.
  • compositions of the subject invention when administered according to the procedures of the subject invention, do not cause deleterious absorption of chlorhexidine, systemic toxicity, or fibrosis.
  • the compositions can be applied to tissue of the nervous system, including tissue of the central nervous system (CNS), without causing deleterious effects.
  • the pyrogen-binding compositions of the subject invention comprise chlorhexidine at a concentration of about 1.0% or less, more preferably at about 0.1% or less, and even more preferably at about 0.05% or less, and for some uses at 0.02% or less. Typically, the compositions would have at least, 0.005%, 0.01%, or 0.02% or more of chlorhexidine. In one embodiment, chlorhexidine dissolved in water can be used according to the subject invention.
  • the subject invention can be useful for inhibiting the bioavailability of the pyrogen in the subject’s body. In other words, the subject invention can be useful for reducing or removing the ability of a pyrogen to induce the symptoms of sepsis, such as, for example, fever, in a subject’s body.
  • a method for inhibiting the bioavailability of a pyrogen in a subject’s body, wherein a composition comprising chlorhexidine gluconate is contacted with the pyrogen.
  • the composition can be contacted with the pyrogen by way of administration to a site in the subject’s body.
  • the site is afflicted with, or susceptible to, a bacterial infection.
  • inhibiting the bioavailability of a pyrogen can comprise rendering the pyrogen inactive or otherwise incapable of inducing the immune response that leads to sepsis. This can be achieved by any number of mechanisms, for example, by changing the configuration of the pyrogen molecule or blocking a binding site on the pyrogen molecule.
  • the method can be used to decrease the amount of bioavailable pyrogens, reduce the number of bioavailable pyrogen molecules, and/or reduce the potency of a pyrogen in a subject’s body.
  • the pyrogen can be an exogenous or endogenous pyrogen.
  • the pyrogen is an exogenous pyrogen produced by bacteria.
  • the pyrogen can be an endotoxin produced by bacteria, such as, for example, a lipopolysaccharide (LPS) endotoxin.
  • the endotoxin-producing bacteria is a Gram-negative bacteria.
  • the endotoxin-producing bacteria is a Gram-positive bacteria.
  • the chlorhexidine composition can also be used to control the endotoxin-producing bacteria itself while inhibiting the bioavailability of a pyrogen.
  • the method may be used to treat and/or prevent a pyrogenic fever, or to treat and/or prevent any other symptom of sepsis in a subject that has, preferably, been diagnosed with a bacterial infection and/or with sepsis.
  • the subject methods comprise contacting the composition, under turbulent conditions, with a site in the subject’s body.
  • the composition can be administered under pressure to the site using a device fitted with a nozzle or head capable of spraying multiple, simultaneous, pressurized streams of liquid.
  • the device is a pressurized wound irrigation device.
  • the administration of the chlorhexidine-containing composition is followed by a rinse with, for example, saline. In other embodiments, no such rinse is applied. Suction may also be applied.
  • the pyrogen-binding composition may have other components including, for example, pH modifiers, buffers, local anesthetic agents, agents that promote wound healing (such as agents that help degrade biofilm), agents that stop bleeding and/or promote clot formation, fever- reducing agents, and other therapeutic and non-therapeutic components.
  • composition of the subject invention can be used at a variety of applications in a variety of bodily sites, such as, for example, a postoperative surgical site, an incision on the skin, the urogenital tract, an implant, a joint, the respiratory tract, an intraperitoneal site, an ocular site, the colon, the sinuses, an intra-articular site, a mediastinal site, a healing tissue site, an intracranial site, a cerebrospinal site, or other nervous system tissue.
  • bodily sites such as, for example, a postoperative surgical site, an incision on the skin, the urogenital tract, an implant, a joint, the respiratory tract, an intraperitoneal site, an ocular site, the colon, the sinuses, an intra-articular site, a mediastinal site, a healing tissue site, an intracranial site, a cerebrospinal site, or other nervous system tissue.
  • the site can be an anastomosis or an anastomotic leak (e.g., after colorectal surgery); a perforated intestinal viscus; a spinal and/or cranial surgical site; a prosthetic joint infection; a cardiac surgery postoperative infection; and/or a urinary tract infection.
  • composition of the subject invention is packaged to facilitate use in a sterile field.
  • the subject invention provides materials and methods for preventing and/or treating sepsis by, for example, decreasing the amount of bioavailable pyrogens in a subject’s body.
  • the subject invention provides compositions and methods of their use for reducing the activity of pyrogenic substances, or pyrogens, in a subject diagnosed with an infection and/or with sepsis, or in a subject at risk of developing sepsis due to, for example, a wound or infection.
  • the compositions of the subject invention are capable of binding to pyrogens and rendering them incapable of inducing the immune response that leads to sepsis and symptoms thereof, e.g., fever.
  • bioavailability of a molecule refers to the ability of the molecule to have an effect at a site of action in a subject’s body.
  • bioavailability of a pyrogen refers to the ability of the pyrogen molecule to induce an immune and/or inflammatory response in the subject’s body.
  • Bioavailability of a pyrogen may also include the ability of the pyrogen molecule to interact with the hypothalamus and induce fever in the subject’s body, and/or the ability of the pyrogen molecule to bind with certain immune response receptors present in or on immune cells to induce an immune response by those cells.
  • the term“subject” refers to an animal, especially a mammal.
  • mammals include humans, non-human primates, dogs, cats, equines, bovines, and pigs.
  • the preferred subject in the context of this invention is a human of any gender and of any age or stage of development, including infant, toddler, child, adolescent, teenager, adult and senior.
  • treatment refers to eradicating, reducing, ameliorating, or reversing, a sign or symptom of a condition or disorder to any extent, and includes, but does not require, a complete cure of the condition or disorder. Treating can be curing, improving, or partially ameliorating a disorder.
  • preventing refers to avoiding, delaying, forestalling, or reducing the onset of a particular sign or symptom of the condition or disorder. Prevention can, but is not required to be, absolute or complete, meaning the sign or symptom may still develop at a later time. Prevention can include reducing the severity of the onset of such a condition or disorder, and/or inhibiting the progression of the condition or disorder to a more severe condition or disorder.
  • transitional term “comprising,” which is synonymous with “including,” or “containing,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.
  • the transitional phrase“consisting of’ excludes any element, step, or ingredient not specified in the claim.
  • the transitional phrase“consisting essentially of’ limits the scope of a claim to the specified materials or steps“and those that do not materially affect the basic and novel characteristic(s)” of the claimed invention.
  • Use of the term“comprising” contemplates other embodiments that “consist” or “consist essentially” of the recited component(s).
  • compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
  • a pyrogen-binding composition is provided, wherein the composition contains an active agent that preferably comprises chlorhexidine. In one embodiment, the composition is sterile.
  • a low concentration solution of chlorhexidine can be used to effectively decrease the amount of bioavailable pyrogen molecules in a subject’s body.
  • Chlorhexidine-containing solutions can be administered to a subject according to the current invention without causing hemolysis or other deleterious effects on the blood, blood cells, or vascular system.
  • the chlorhexidine-containing solutions of the subject invention do not result in deleterious absorption of chlorhexidine, systemic toxicity, or fibrosis.
  • the compositions of the subject invention can be applied to tissue of the nervous system, including tissue of the central nervous system (CNS), without causing deleterious effects.
  • CNS central nervous system
  • chlorhexidine-containing solutions in novel and advantageous ways, as described herein, to effectively decrease the amount of bioavailable pyrogenic substances in a subject’s body, as well as to treat and/or prevent infections and the complications associated therewith (e.g., sepsis and/or pyrogenic fever) in a wide range of tissues and locations in or on a subject.
  • the sterile pyrogen-binding composition contains an active agent that preferably comprises chlorhexidine at a concentration of about 2% w/v or less, about 1% w/v or less, about 0.1 % w/v or less, about 0.05% w/v or less, about 0.025% w/v or less, or about 0.02% w/v or less.
  • the composition would have at least, 0.005%, 0.01%, or 0.02% or more of chlorhexidine.
  • the chlorhexidine concentration is from 0.02% w/v to 0.05% w/v.
  • the chlorhexidine can be, for example, chlorhexidine gluconate (CHG), chlorhexidine acetate, chlorhexidine hydrochloride, or a combination thereof.
  • the chlorhexidine may also be modified with, for example, a phosphate group to enhance efficacy, further reducing the likelihood of the development of resistant microbes.
  • the pyrogen-binding composition can further contain one or more additional active agents.
  • the composition contains no alcohol, or less than 1%, 4%, 5%, 10%, 25%, or 50% alcohol.
  • CHG used according to the subject invention has the following chemical structure:
  • the pH of the pyrogen-binding composition is preferably neutral or slightly acidic.
  • the pH is 5.0 to 7.5. More preferably the pH is 5.5 to 7.0.
  • the subject compositions can be useful for inhibiting the bioavailability of the pyrogen in the subject’s body.
  • the subject invention can be useful for reducing or removing the ability of a pyrogen to induce the symptoms of sepsis, such as, for example, fever, in a subject’s body.
  • a method for inhibiting the bioavailability of a pyrogen in a subject’s body, wherein a composition comprising chlorhexidine gluconate is contacted with the pyrogen.
  • the composition can be contacted with the pyrogen by way of administration to a site in the subject’s body where the pyrogen is located or produced.
  • the site has a bacterial infection.
  • the method can comprise the steps of: (a) providing a sterile pyrogenbinding composition comprising an active agent comprising chlorhexidine at a concentration of about 2% or less; and (b) administering the sterile pyrogen-binding composition, directly or indirectly, to a site in the subject, wherein the site is afflicted with a bacterial infection.
  • the method can be used to decrease the amount of bioavailable pyrogen producing agents, reduce the number of bioavailable pyrogen molecules, and/or reduce the potency of a pyrogen in a subject’s body.
  • the method can be used to reduce a pyrogenic fever in a subject diagnosed with pyrogenic fever.
  • the method can be used to treat and/or prevent sepsis, septic shock or septicemia in a subject that has, preferably, been diagnosed with an infection and/or with sepsis, septic shock or septicemia.
  • inhibiting the bioavailability of a pyrogen can comprise rendering the pyrogen inactive or otherwise incapable of inducing the immune response that leads to sepsis. This can be achieved by any number of mechanisms, for example, by changing the configuration of the pyrogen molecule or blocking a binding site on the pyrogen molecule.
  • a chlorhexidine in the composition of the subject invention binds with a pyrogen to inhibit the pyrogen molecule’s bioavailability.
  • the pyrogen can be an exogenous or endogenous pyrogen.
  • the pyrogen is an exogenous pyrogen produced by bacteria.
  • the pyrogen is an endotoxin produced by bacteria, such as, for example, a lipopolysaccharide (LPS) endotoxin.
  • LPS lipopolysaccharide
  • the endotoxin-producing bacteria is a Gram-negative bacteria. In another embodiment, the endotoxin-producing bacteria is Gram-positive.
  • the chlorhexidine composition can also be used to control the endotoxin-producing bacteria itself while inhibiting the bioavailability of a pyrogen.
  • the pyrogen-binding composition and methods of the current invention can be used in a variety of applications in a variety of bodily sites, such as, for example, a postoperative surgical site, an incision on the skin, the urogenital tract, an implant, a joint, the respiratory tract, an intraperitoneal site, an ocular site, the colon, the sinuses, an intra-articular site, a mediastinal site, a healing tissue site, an intracranial or cerebrospinal site, or other nervous system tissue.
  • bodily sites such as, for example, a postoperative surgical site, an incision on the skin, the urogenital tract, an implant, a joint, the respiratory tract, an intraperitoneal site, an ocular site, the colon, the sinuses, an intra-articular site, a mediastinal site, a healing tissue site, an intracranial or cerebrospinal site, or other nervous system tissue.
  • the site can be an anastomosis; a colorectal surgery postoperative anastomotic leak; a perforated intestinal viscus; a spinal and/or cranial surgical site infection; a prosthetic joint infection; a cardiac surgery postoperative infection; and/or a urinary tract infection.
  • the administration of the pyrogen-binding composition of the present invention to a site in a subject’ s body results in a reduction in the amount of bioavailable pyrogens in the body while also reducing the number of bacteria or other microbes at the site, when compared to either an untreated site or a site administered with saline or water that does not contain chlorhexidine.
  • administration of the pyrogen-binding composition according to the subject invention can result in effective reduction of pyrogen activity, effective control of an infection, and in some embodiments, effective treatment and/or prevention of sepsis and/or pyrogenic fever, without causing tissue damage.
  • additional active agents that can be administered to a subject in accordance with the subject invention include, but are not limited to, anti-bacterial agents, anti-viral agents, fungicidal agents, chemotherapeutic agents, topical antiseptics, anesthetic agents, fever-reducers, oxygenated fluids and/or agents, antibiotics, diagnostic agents, homeopathic agents, agents that stop bleeding, and over-the-counter medications/agents.
  • the subject may receive, for example, vancomycin, ceftriaxone, ceftin, cefuroxime, or tobramycin.
  • the additional agent can be an anti-microbial peptide (AMP).
  • AMPs are well known in the art.
  • the subject may also receive an intravenous fluid and/or a vasopressor.
  • the additional agent is a diagnostic agent.
  • the diagnostic agent may be, for example, an antibody, protein, or polynucleotide that binds to a target biomolecule. Any such binding may then be visualized utilizing technologies known to those skilled in the art.
  • a plain aqueous solution of the active agent comprises the active agent and/or a second agent in a solution of water that is essentially devoid of solutes that provide osmolarity to the solution, for example, a salt or a sugar.
  • an isotonic solution refers to a solution having the same osmotic pressure as blood.
  • isotonic solutions contain about 0.85% of NaCl in water.
  • an isotonic solution containing the active agent according to the current invention refers to a solution of the active agent and/or a second agent in about 0.85% NaCl in water.
  • Chlorhexidine is capable of binding to pyrogens in a subject’s body and rendering them bio-unavailable, or inactive, within the body.
  • the pyrogen is an endogenous pyrogen, released by a monocyte, neutrophil, lymphocyte, endothelium glial cells, mesangial and/or mesenchymal cell in the subject’s body.
  • exemplary endogenous pyrogens include cytokines, such as, for example, interleukin-6 (IL-6), IL-l, tumor necrosis factor (TNF), interferon-alpha and/or gpl30 receptor ligands.
  • the pyrogen is an exogenous pyrogen produced by, for example, a microorganism.
  • the exogenous pyrogen can be an endotoxin, such as a lipopolysaccharide (LPS) complex associated with the outer membrane of Gram-negative bacterial cells of, for example, Bordetella pertussis , Escherichia coli , Haemophilus influenzae, Klebsiella spp., Pseudomonas aeruginosa, Salmonella enterica, Staphylococcus aureus, Streptococcus pyogenes, Shigella, Neisseria, and Vibrio cholerae.
  • the endotoxin is associated with a Gran-positive bacteria.
  • LPS molecules comprise three covalently joined regions: a lipid, a core oligosaccharide, and O-antigen.
  • the molecule is anchored into the bacterial membrane by the“lipid A” domain, which comprises hydrophobic fatty acid chains, while the remainder of the molecule extends from the cell surface.
  • the endotoxin fragments bind to receptors and proteins in the cell membranes of macrophages, e.g., CD14, mannose binding protein and toll like receptors, to activate the release of pro-inflammatory mediators, e.g., IL-l and TNF- a, against the invading pathogens; however, this immune response can become so strong that it can result in, for example, fever, changes in blood pressure, diarrhea, tissue and organ failure, and/or death, i.e., septic shock or endotoxic shock.
  • pro-inflammatory mediators e.g., IL-l and TNF- a
  • the chlorhexidine in the compositions of the subject invention is capable of binding the lipid A portion of LPS and rendering it incapable of inducing the immune response that leads to sepsis.
  • chlorhexidine in addition to its pyrogen-binding capabilities, chlorhexidine is also capable of controlling (e.g. , killing and/or eliminating) aerobic and anaerobic Gram-positive and Gram-negative bacteria. Chlorhexidine also has activity against Chlamydia trachomatis, certain fungi, and certain viruses.
  • bacteria against which chlorhexidine is effective include a variety of Gram-positive aerobic bacteria, such as, e.g., Streptococcus mutants, S. pyogenes (group A b-hemolytic streptococci), S. salivarius, and S. sanguis ⁇ , Staphylococcus aureus (e.g., S. epidermidis, S. haemolyticus, S. hominis, and S.
  • Gram-positive aerobic bacteria such as, e.g., Streptococcus mutants, S. pyogenes (group A b-hemolytic streptococci), S. salivarius, and S. sanguis ⁇ , Staphylococcus aureus (e.g., S. epidermidis, S. haemolyticus, S. hominis, and S.
  • simulans both oxacillin-resistant (ORSA) and oxacillin- susceptible staphylococci (also known as methicillin-resistant [MRSA] or methicillin-susceptible staphylococci); Enterococcus (e.g., E.faecalis and E.faecium) and both vancomycin-susceptible and vancomycin-resistant strains of bacteria.
  • ORSA oxacillin-resistant
  • MRSA methicillin-resistant
  • Enterococcus e.g., E.faecalis and E.faecium
  • vancomycin-susceptible and vancomycin-resistant strains of bacteria e.g., E.faecalis and E.faecium
  • Chlorhexidine is also capable of controlling some anaerobic bacteria, such as, for example, some strains of Bacteroides, Propionibacterium, Clostridium difficile, and Selenomonas, but is less active against Veillonella.
  • Chlorhexidine can control Candida (e.g., C. albicans , C. dubliniensis, C. glabrata (formerly Torulopsis glabrata), C. guillermondii, C. kefyr (formerly C. pseudotropicalis), C. krusei, C. lusilaniae, and C. tropicalis (formerly C. parapsilosi )); and some dermatophytes, including Epidermophyton floccosum, Microsporum gypseum, M. canis, and Trichophyton mentagrophytes.
  • the sterile pyrogen binding composition of the subject invention can also“depathogenize” certain bacteria including, for example, Escherichia coli and Klebsiella aerogenes, making these bacteria less potent to cause infection.
  • Chlorhexidine also has antiviral activity against viruses that have a lipid component in their outer coat or have an outer envelope such as cytomegalovirus (CMV), human immunodeficiency virus (HIV), herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), influenza virus, parainfluenza virus, and variola virus (smallpox virus).
  • CMV cytomegalovirus
  • HAV human immunodeficiency virus
  • HSV-1 herpes simplex virus types 1
  • HSV-2 herpes simplex virus types 1
  • influenza virus parainfluenza virus
  • variola virus smallpox virus
  • the methods of the subject invention can be used in conjunction with the delivery of a chlorhexidine-containing solution by many routes.
  • routes Of particular interest are: cutaneous, intra abdominal, intracranial, intralesional, intrathoracic (during surgery), nasal, otic (in the ear canal), as a gastric lavage, ocular (as an eye wash), periodontal, rectal, soft tissue, oral, subcutaneous, and vaginal routes.
  • Chlorhexidine solutions of the subject invention can be administered using any of a wide range of currently- available delivery devices, systems, and methods.
  • the composition is contacted with a site in the subject’s body under turbulent rather than laminar conditions.
  • the composition can be administered under pressure to the site using a device fitted with a nozzle or head capable of spraying single or multiple, simultaneous pressurized streams of liquid.
  • the device is a wound irrigator fitted with such a nozzle or head.
  • the active flow of fluid under pressure can remove bacteria and particulate matter.
  • the turbulence and increased mixing of the solution with body fluids can lead to greater binding of pyrogens with chlorhexidine, i.e., greater reduction in the number of bioavailable pyrogen molecules.
  • composition can also be delivered via an intravenous fluid line, a catheter, a syringe, or as a spray, shower or mist, and/or orally (e.g., as a capsule or tablet).
  • the subject invention also provides a sepsis treatment kit comprising a composition comprising chlorhexidine and also having in the kit at least one antibiotic.
  • the subject invention further provides an intravenous tube or fluid bag containing a fluid comprising chlorhexidine and an antibiotic.
  • the invention provides an aqueous composition consisting of, consisting essentially of, or comprising chlorhexidine and an antibiotic.
  • the sterile pyrogen-binding composition can be administered to an internal surgical site (or other site of infection or potential infection) via depositing a porous material containing the active agent (e.g., chlorhexidine) that releases the active agent over a period of time to the site.
  • the active agent e.g., chlorhexidine
  • the presence of the active agent in and around the site can prevent and/or treat an infection; reduce the amount of bioavailable pyrogens at the site; and/or prevent or treat sepsis and/or pyrogenic fever resulting from an infection.
  • the porous material containing the active agent can be administered to a surgical site when the surgery is performed.
  • the porous material is a disc, a sphere, or a shape designed to fit at the site.
  • the porous material containing the active agent can release the active agent over a period of about 1 hour to about 6 months, about 2 months to about 5 months, about 3 months to about 4 months, about 1 week to about 4 weeks, about 2 weeks to about 3 weeks, or any other permutation of these time periods.
  • Non-limiting examples of materials that can be used to produce the porous implants include silicate feldspar matrix, hydroxyapatite, porous titanium, or sponge. Additional examples of materials appropriate to produce sustained release implants are well known to a person of ordinary skill in the art and such materials are within the purview of the current invention. For example, hydrogels or other such coatings that incorporate therein chlorhexidine can also be used.
  • the pyrogen-binding composition is administered to a site of healing tissue.
  • a healing tissue site is an area of the tissue that suffered an injury or a disease and is recovering after the treatment for the injury or the disease (e.g., after surgery).
  • a healing tissue site can be at the surface of the skin or internal.
  • the pyrogen-binding composition is administered to a healing tissue site via a patch, biodegradable gel, bandage, or dressing containing the chlorhexidine; a thick viscous solution containing the chlorhexidine; or a suture containing chlorhexidine.
  • chlorhexidine binds to healing tissues, for example, to sub-cutaneous layers of skin, to provide antimicrobial, anti-pyrogen, and healing effects.
  • the sterile composition provides an active agent that can bind to a healing tissue to enhance healing tissue recovery, prevent infection, treat an existing infection, and/or reduce the bioavailability of pyrogenic substances produced by an infection.
  • the sterile pyrogen-binding composition can be administered to a site as a tablet taken orally, microcapsule delivery spheres, nanoparticles, targeted nanoparticles (for example, receptor mediated targeted nanoparticles), a time controlled delivery system, a frozen block of the sterile pyrogen binding composition, a plain aqueous solution of the active agent, an isotonic solution of the active agent, or an implantable time release delivery system.
  • the pyrogen-binding composition is left at the site after administration thereto.
  • the site or tissue is optionally rinsed with, for example, a sterile solution free of the active agent.
  • Suction negative pressure
  • solutions free of the active agent include, but are not limited to, plain water, saline, and isotonic solutions free of the active agent.
  • the rinsing can be performed by administering the solution free of the active agent to the site and removing the resultant solution from the site or the tissue by, for example, suction.
  • the rinsing is performed within about 1 minute to about 10 minutes, about 2 minutes to about 5 minutes, or about 3 minutes from the time of administering the sterile pyrogen-binding composition to the site in the subject.
  • suction is performed, with or without rinsing.
  • the methods of the subject invention are utilized by trained medical technicians; however, because of the simplicity and convenience of the subject invention, they can be used to greatly enhance the effectiveness of the administration of the pyrogen binding composition regardless of the training level of the operator performing the irrigation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des matériaux et des procédés pour réduire la quantité de pyrogènes biodisponibles dans le corps d'un sujet. De manière avantageuse, par application d'une composition comprenant du gluconate de chlorhexidine sur un site du corps d'un sujet, par exemple, un site qui est atteint d'une infection bactérienne, les procédés peuvent être utilisés pour traiter et/ou prévenir le sepsis et/ou la fièvre pyrogène chez le sujet.
PCT/US2019/038618 2018-06-26 2019-06-22 Composition de liaison de pyrogène et son utilisation dans le traitement et la prévention du sepsis Ceased WO2020005785A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862690019P 2018-06-26 2018-06-26
US62/690,019 2018-06-26

Publications (1)

Publication Number Publication Date
WO2020005785A1 true WO2020005785A1 (fr) 2020-01-02

Family

ID=68987449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/038618 Ceased WO2020005785A1 (fr) 2018-06-26 2019-06-22 Composition de liaison de pyrogène et son utilisation dans le traitement et la prévention du sepsis

Country Status (1)

Country Link
WO (1) WO2020005785A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164829A1 (en) * 2013-12-12 2015-06-18 Innovation Technologies, Inc. Materials and methods for controlling infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164829A1 (en) * 2013-12-12 2015-06-18 Innovation Technologies, Inc. Materials and methods for controlling infections

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BICALHO PAULO ROBERTO RODRIGUES ET AL.: "Treatment with chlorhexidine modifies the healing of colon anastomosis in rats", JOURNAL OF INVESTIGATIVE SURGERY, vol. 24, no. 1, 2011, pages 8 - 12 *
BONDAR VICTOR M. ET AL.: "Chlorhexidine lavage in the treatment of experimental intra-abdominal infection", ARCH SURG., vol. 135, no. 3, 2000, pages 309 - 314, XP055666723 *
LITVITSKIY P.F.: "Violations of the heat balance. Fever", QUESTIONS OF MODERN PEDIATRICS, vol. 8, 2009, pages 55 - 63 *
SEGERS PATRIQUE ET AL.: "Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial", JAMA, vol. 296, no. 20, 2006, pages 2460 - 2466, XP055666727 *
SULTONOV SH.R. ET AL., COMPLEX DIAGNOSIS AND TREATMENT OF TYPHOID PERITONITIS AMONG CHILDREN, vol. 3, no. 1, 2013, pages 40 - 43 *

Similar Documents

Publication Publication Date Title
US11559503B2 (en) Materials and methods for controlling infections
KR20220027799A (ko) 항미생물제 내성의 유도 없이 생물막을 치료하기 위한 조성물
CN110402084A (zh) 包含乙酸和次氯酸的组合物以及处理生物膜的方法
AU2017347819A1 (en) Materials and methods for the control of biofilm
US20190117569A1 (en) Compositions and methods for reducing infection in wounds and surgical sites
Hananeh et al. Effects of Sidr honey on second-intention healing of contaminated full-thickness skin wounds in healthy dogs
EP3177333A1 (fr) Matériaux et procédés pour lutter contre les infections avec traitement des plaies par pression négative
HK40017056A (en) Materials and methods for the control of biofilm
HK1227710A1 (en) Materials and methods for controlling infections
Pasechnikov et al. Decasan in the treatment of infected wounds after urological surgeries

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19827210

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 04.05.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19827210

Country of ref document: EP

Kind code of ref document: A1